Compare GSK plc (GSK) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Royal Caribbean Cruises Ltd — how do they compare? GSK plc trades at $51.53 (market cap $101.34B), while Royal Caribbean Cruises Ltd trades at $292 (market cap $78.36B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | RCL | |
|---|---|---|
Market Cap | $101.34B | $78.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $365.84 |
52-Week Low | $36.20 | $246.71 |
Enterprise Value | $121.95B | $99.64B |
Dividend Yield | 3.49% | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Royal Caribbean (RCL) trades at $283.09, down 1.91% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. Fundamentally, the company demonstrates strong profitability with 24.36% net margins and 50.41% ROE, supported by consistent revenue growth from $8.8B in 2022 to $17.9B in 2025. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed.
The stock offers 16% upside to the consensus price target of $328, with analysts maintaining a buy-heavy stance (48% buy ratings). Key risks include Europe weakness offset by Caribbean strength, high debt levels, and competitive pressures. Cash flow trends show improving operational performance with $6.5B operating cash flow in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
